4//SEC Filing
GORMAN KEVIN CHARLES 4
Accession 0000914475-25-000073
CIK 0000914475other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 6:57 PM ET
Size
15.3 KB
Accession
0000914475-25-000073
Insider Transaction Report
Form 4
GORMAN KEVIN CHARLES
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2025-02-13+5,376→ 524,450 total - Sale
Common Stock
2025-02-13$116.68/sh−3,012$351,450→ 524,209 total - Exercise/Conversion
Common Stock
2025-02-13+5,603→ 527,221 total - Sale
Common Stock
2025-02-13$116.69/sh−2,832$330,465→ 521,618 total - Exercise/Conversion
Restricted Stock Unit
2025-02-13−5,376→ 10,754 total→ Common Stock (5,376 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-13−5,603→ 16,812 total→ Common Stock (5,603 underlying)
Footnotes (8)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.92 to $117.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F4]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $117.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
- [F6]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F7]This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, and will vest as to 5,377 shares on February 13, 2026, and 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.
- [F8]This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, and will vest as to 5,604 shares on February 13, 2026, 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001201096
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 6:57 PM ET
- Size
- 15.3 KB